DepoMed to buy U.S. rights to Nucynta from J&J unit By: MarketWatch January 15, 2015 at 16:48 PM EST DepoMed agrees to buy the U.S. license rights to the painkiller Nucynta from Janssen Pharmaceuticals, a unit of Johnson & Johnson, for $1.05 billion. Read More >> Related Stocks: Depomed Inc Johnson & Johnson